Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs

Annals of Pharmacotherapy

Volumn 34, Issue 7-8, 2000, Pages 915-923

  Reddy, K Rajender ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Controlled release; Liposomes; Polyethylene glycol; Polylactic acid; Polymers

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ASPARAGINASE MACROGOL; CONTRAST MEDIUM; DOXORUBICIN; GOSERELIN; LEUPRORELIN; LIPOSOME; M PROTEIN; MACROGOL; PEGADEMASE; PEPTIDE; POLY(3 HYDROXYBUTYRIC ACID); POLYGLACTIN; POLYLACTIC ACID; POLYMER;

AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; CONTROLLED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG HALF LIFE; ENCAPSULATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0033928514     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10054     Document Type: Article

References (63)

1. Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 1991;6:133-51.
2. Fuertges F, Abuchowski A. The clinical efficacy of polyethylene glycol-moditied proteins. J Controlled Release 1990;11:139-48.
3. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995;12:1-99.
4. Ogawa Y. Injectable microcapsules prepared with biodegradable poly(α-hydroxy) acids for prolonged release of drugs. J Biomater Sci Polym Ed 1997;8:391-409.
5. Yewey GL, Duysen EG, Cox SM, Dunn RL. Delivery of proteins from a controlled release injectable implant. Pharm Biotechnol 1997;10:93-117.
6. Eppstein DA, Longenecker JP. Alternative delivery systems for peptides and proteins as drugs. Crit Rev Ther Drug Carrier Syst 1988;5:99-139.
7. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997;28: 43-70.
8. Sandow J, Stoeckemann K. Jerabek-Sandow G. Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. J Steroid Biochem Mol Biol 1990;37:925-31.
9. Okada H, Inoue Y, Heya T, Ueno H, Ogawa Y, Toguchi H. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm Res 1991;8:787-91.
10. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996;2:795-9.
11. Cleland JL, Jones AJS. Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable microspheres. Pharm Res 1996;13:1464-75.
12. Cleland JL, Mac A, Boyd B, Yang J, Duenas ET, Yeung D, et al. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 1997;14:420-5.
13. Heya T, Mikura Y, Nagai A, Miura Y, Futo T, Tomida Y, et al. Controlled release of thyrotropin releasing hormone from microspheres: evaluation of release profiles and pharmacokinetics after subcutaneous administration. J Pharm Sci 1994;83:798-801.
14. Calis S, Jeyanthi R, Tsai T, Mehta RC, DeLuca PP. Adsorption of salmon calcitonin to PLGA microspheres. Pharm Res 1995;12:1072-6.
15. Storm G, Crommelin DJA. Colloidal systems for tumor targeting. Hybridoma 1997;16:119-25.
16. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997;54 (suppl 4):8-14.
17. Bakker-Woudenberg IAJM, Storm G, Woodle MC. Liposomes in the treatment of infections. J Drug Target 1994;2:363-71.
18. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Drugs 1997;54(suppl 4):15-21.
19. Khalifa A, Dodds D, Rampling R, Paterson J, Murray T. Liposomal distribution in malignant glioma: possibilities for therapy. Nucl Med Commun 1997;18:17-23.
20. Wasan KM, Lopez-Berestein G. The past, present, and future uses of liposomes in treating infectious diseases. Immunopharmacol Immunotoxicol 1995;17:1-15.
21. Margalit R. Liposome-mediated drug targeting in topical and regional therapies. Crit Rev Ther Drug Carrier Syst 1995;12:233-61.
22. Shek PN, Suntres ZE, Brooks JI. Liposomes in pulmonary applications: physiochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 1994;2:431-42.
23. Leander P, Höglund P, Kloster Y, Børseth A. New liposomal liver-specific contrast for CT: first human Phase I clinical trial assessing efficacy and safety. Acad Radiol 1998;5(suppl 1):S6-8.
24. Höglund P, Leander P, Hustvedl SO, Kloster Y, Børseth A. Human pharmacokinetics and modeling of the concentration - attenuation relationship of a new liposomal liver-specific contrast agent for CT. Acad Radiol 1998;5(suppl 1):S47-8.
25. Leenders AC, de-Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996;10:1570-5.
26. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994;8:431-50.
27. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(suppl 2):S133-44.
28. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-8.
29. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998;15:57-88.
30. Francis GE, Delgado C, Fisher D, Malik F, Agrawal AK. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J Drug Target 1996;3:321-40.
31. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997;54(suppl 4):30-5.
32. Amantea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 1997;61:301-11.
33. Muggia FM. Clinical efficacy and prospects for the use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997;54(suppl 4):22-9.
34. Suzuki S, Watanabe S, Masuko T, Hashimoto Y. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with polyethylene glycol. Biochem Biophys Acta 1995;1245:9-16.
35. Nam SM, Kim HS, Ahn WS, Park YS. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Oncol Res 1999;11:9-16.
36. Pagnan G, Montaldo PG, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, et al. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 1999;81:268-74.
37. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998;1:352-6.
38. Zalipsky S, Lee C. Use of functionalized poly(ethylene glycol)s for modification of polypeptides. In: Harris J, ed. Poly(ethylene glycol) chemistry: biotechnical and biomedical applications. New York: Plenum Press, 1992:347-70.
39. Site-directed pegylation of proteins. In: Shearwater Polymers, quarterly newsletter. Huntsville, AL: Shearwater Polymers, 1998:1-2.
40. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Camer Syst 1992;9:249-304.
41. Fung W-J, Porter JE, Bailon P. Strategies for the preparation and characterization of polyethylene glycol (PEG) conjugated pharmaceutical proteins. Polymer Preprints 1997;38:565-6.
42. Zalipsky S, Harris JM. Introduction to chemistry and biological applications of poly(ethylene glycol). In: Harris JM, Zalipsky S, eds. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997:1-15.
43. Working PK, Newman MS, Johnson J, Cornacoff JB. Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives. In: Harris JM, Zalipsky S, eds. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997:45-59.
44. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998;42:153-7.
45. Hershfield MS. Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In: Harris JM, Zalipsky S. eds. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997:145-54.
46. Hilman BC, Sorensen RU. Management options: SCIDS with adenosine deaminase deficiency. Ann Allergy 1994;72:395-404.
47. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316: 589-96.
48. Davis R, Abuchowski A, Van Es T, Palczuk NC, Chen R, Savoca K, et al. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Engineering 1978;4:169-73.
49. Davis S, Abuchowski A, Park Y, Davis FF. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 1981;46:649-52.
50. Keating MJ, Holmes R, Lerner S, Ho DH. L-Asparaginase and PEG asparaginase - past, present, and future. Leuk Lymphoma 1993;10(suppl): 153-7.
51. Holle LM. Pegaspargase: an alternative? Ann Pharmacother 1997;31: 616-24.
52. Burnham NL. Polymers for delivering peptides and proteins. Am J Hosp Pharm 1994;51:210-8.
53. Tsutsumi Y, Tsunoda S, Kamada H, KihiraT, Kaneda Y, Ohsugi Y, et al. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 1997;77:168-73.
54. Campbell RM, Heimer EP, Ahmad M, Eisenbeis HG, Lambros TJ, Lee Y, et al. Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. J Peptide Res 1997;49:527-37.
55. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996;97:2145-51.
56. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimized brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharmaceut Res 1998;15:576-82.
57. Truitt GA, Tarby CM, Stern LL, Tamborini B, Bontempo JB, Nalin C, et al. Pharmacodynamic and preliminary pharmacokinetic evaluation of pegylated derivatives of interferon-alfa 2a (abstract). Proceedings from the Annual Meeting of the American Association of Cancer Research, San Francisco, CA, April 10-13, 1994:398.
58. Xu Z-X, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-inlerferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects (abstract). Hepatology 1998;28(suppl):702.
59. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996;59:636-46.
60. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-31.
61. Sy S, Algranati NE, Patel IH, Modi M. Cytochrome P450 (CYP)-mediated drug interactions are unlikely with peginterferon α-2a (PEG-IFN) except for CYP1A2 (abstract). Hepatology 1999;30(suppl):193A.
62. Shiffman M, Pockros PJ, Reddy RK, Wright RL, Reindollar R, Fried MW, et al. A controlled, randomized, multicenter, descending dose Phase II trial of pegylated interferon alfa-2a (PEG) vs. standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C (abstract). Gastroenterology 1999;116:1275.
63. Glue P, Fang J, Sabo R, Rouzier-Panis R, Raffanel C, Gupta SK, et al. Peg-interferon-alfa-2b: pharniacokinetics, pharmacodynamics, safety and preliminary efficacy data (abstract). Hepatology 1999;30(suppl): 189A.